CATALYST DOSSIER · UPDATED 2026-11-05
$PINS
tech · convergence -24 · conviction AVOID
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $PINS?
Quantitative
Net Income (CY2026Q2) : $-46.7M (-220.4% YoY)
Catalysts
Multi-spoke convergence : 8 convergent signals fired: finra_short, sc13d, github, finra_regsho, auto_edgar_fulltext
Risks
Hard-to-borrow / FTD risk : Borrow rate 6.0%, distress score 30
Bear case
Squeeze unwind : Short interest can compress before retail catches the move — entry timing critical
Sympathy basket (cerebro)
DIOD via semis r=+0.89 sympathetic (score 11)
ARRY via semis r=+0.89 sympathetic (score 9)
CRIS via biotech r=+0.81 sympathetic (score 26)
LMAT via biotech r=+0.81 sympathetic (score 20)
LBTYA via comms r=+0.57 sympathetic (score 16)
CHTR via comms r=+0.57 sympathetic (score 7)
Signals Firing
finra_short sc13d github finra_regsho auto_edgar_fulltext auto_macro_adp_payrolls auto_macro_durable_goods auto_macro_fx_rates
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-10-15 sec_top_gappers +0.8% -3.5% — 2026-10-15 sec_top_moat_emerging +0.8% -3.5% — 2026-10-05 sec_top_gappers +1.2% -0.1% — 2026-10-05 sec_top_moat_emerging +1.2% -0.1% — 2026-10-02 sec_top_gappers +4.5% +4.2% ✓ hit 2026-10-02 sec_top_moat_emerging +4.5% +4.2% ✓ hit 2026-09-30 sec_top_gappers +3.1% +3.0% ✓ hit 2026-09-30 sec_top_moat_emerging +3.1% +3.0% ✓ hit
Lifetime: 4/8 wins · hit-rate 50.0% on +2% intraday
Sympathy Basket DIOD via semis · score 11 ARRY via semis · score 9 CRIS via biotech · score 26 LMAT via biotech · score 20 LBTYA via comms · score 16 CHTR via comms · score 7
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.